CC
SGMO

Cannell & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cannell & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,200
Closed -$159K – 290
2020
Q4 		$159K Hold
10,200
– – 0.01% 260
2020
Q3 		$96K Hold
10,200
– – ﹤0.01% 240
2020
Q2 		$91K Hold
10,200
– – ﹤0.01% 237
2020
Q1 		$65K Buy
+10,200
New +$75.7K ﹤0.01% 226
2016
Q4 		– Sell
-31,750
Closed -$147K – 258
2016
Q3 		$147K Hold
31,750
– – 0.01% 253
2016
Q2 		$184K Hold
31,750
– – 0.01% 249
2016
Q1 		$192K Buy
31,750
+21,750
+218% +$131K 0.01% 246
2015
Q4 		$91K Buy
+10,000
New +$77.1K ﹤0.01% 257

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cannell & Co's SGMO Position: Q1 2021 in Review

Cannell & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2021, closing a stake of 10,200 shares — an estimated $159K sold.

Cannell & Co first reported a position in SGMO in Q4 2015 and held it in 8 quarters. The position peaked at $192K in Q1 2016. 203 funds tracked by Wall St. Rank hold SGMO as of Q1 2021.

  • Cannell & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
  • Cannell & Co sold 10,200 SANGAMO THERAPEUTICS INC shares in Q1 2021, an estimated $159K.
  • Cannell & Co first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 8 quarters.
  • Cannell & Co's SANGAMO THERAPEUTICS INC position peaked at $192K in Q1 2016.
  • 203 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2021.

Based on Cannell & Co's 13F filing for Q1 2021, filed 7 May 2021.